Key findings: weight loss, safety & tolerability, discontinuation The research revealed several significant insights: Greater weight loss with tirzepatide: Most adults with overweight or obesity experienced 5% or greater weight loss with either treatment
Vierteljahresschrift der Naturforschenden Gesellschaft in Zrich
Many patients safely transition from semaglutide to tirzepatide when a qualified medical provider reviews their health history, goals, side effects, and medication response first
Long-term cardiovascular benefits include sustained reductions in blood pressure and improvements in metabolic markers like cholesterol and inflammation
It works well for those with demanding morning schedules, early gym sessions, or physically active jobs where feeling unwell is not an option
This practice is known as off-label prescribing and is often a perfectly valid use for a particular medication